

Dermatology Referral Form

PATIENT INFORMATION

Patient Name _____
 Address _____
 City _____ State _____ ZIP _____
 Home Phone _____ Cell _____
 DOB _____ SSN _____
 Drug Allergies _____ Male Female

PRESCRIBER INFORMATION

Prescriber Name _____ DEA _____
 NPI# _____ Tax ID _____
 Practice Name _____
 Address _____ Suite _____
 City _____ State _____ ZIP _____
 Office Phone _____ Fax _____

INSURANCE, MEDICARE OR MEDICAID INFORMATION

Primary Prescription Insurance _____ Secondary Prescription Insurance (if applicable) _____
 Policy _____ Group _____ Policy _____ Group _____
 Insurance Phone _____ Insurance Phone _____

COMPLETE OR FAX FRONT AND BACK COPIES OF INSURANCE, PRESCRIPTION AND/OR CO-PAY ASSISTANCE CARDS

CLINICAL INFORMATION

Diagnosis L40 Psoriasis L40.52 Psoriasis Arthritis L73.2 Hidradenitis (HS) Other _____ Location of psoriasis: Hands Feet Scalp Groin Nails Other
 Severity of psoriasis: Mild (up to 3% BSA) Moderate (3-10% BSA) Severe (>10% BSA) BSA _____% Previously treated for this condition? Yes No
 Medication/Therapy: Topical _____ Other _____
 Is patient currently on therapy? Yes No Type/medication(s): _____ Patient tested for TB/PPD? Yes No Results: _____
 Will patient stop the above medication(s) before starting the new medication? Yes No If yes, how long before starting the new medication?: _____

PLEASE ATTACH A LIST OF PATIENTS'S CURRENT MEDICATIONS.

DRUG NAME	PRESCRIPTION ORDERS (PLEASE CHECK ONE OR MORE)	QTY	REFILLS	
Cosentyx® Limited Distribution	<input type="checkbox"/> 150mg Senoready Pen <input type="checkbox"/> 150mg Prefilled syringe	<input type="checkbox"/> Induction: Inject 300 mg subcutaneously at Weeks 0, 1, 2, 3. <input type="checkbox"/> Maintenance: Inject 300mg subcutaneously every 4 weeks starting at week 4.	28 Day Supply	0
			28 Day Supply	
Dupixent®	<input type="checkbox"/> 300mg Prefilled syringe	<input type="checkbox"/> Induction: Inject 600mg (2 syringes) subcutaneously on day 1, begin maintenance on day 15. <input type="checkbox"/> Maintenance: Inject 300mg subcutaneously every other week	14 Day Supply	0
			28 Day Supply	
Enbrel®	<input type="checkbox"/> 50mg Sureclick <input type="checkbox"/> 50mg Prefilled syringe <input type="checkbox"/> Mini	<input type="checkbox"/> Induction: Inject 50mg subcutaneously twice weekly for three months then maintenance dose <input type="checkbox"/> Maintenance: Inject 50mg subcutaneously weekly <input type="checkbox"/> Other _____	84 Day Supply	0
			28 Day Supply	
Enbrel®	<input type="checkbox"/> 25mg Vial kit <input type="checkbox"/> 25mg Prefilled syringe	<input type="checkbox"/> Inject 25mg subcutaneously twice weekly <input type="checkbox"/> Other _____	28 Day Supply	
<input type="checkbox"/> Humira® <input type="checkbox"/> Humira®-Citrate Free	<input type="checkbox"/> 40mg Pen <input type="checkbox"/> 40mg Prefilled syringe	<input type="checkbox"/> Psoriasis Induction: Inject 80mg subcutaneously on day 1, followed by 40mg every other week starting on day 8	1 starter kit	0
		<input type="checkbox"/> Psoriasis Maintenance: Inject 40mg subcutaneously every other week	28 Day Supply	
		<input type="checkbox"/> HS Induction: Inject 160mg subcutaneously on day 1, then 80mg on day 15, maintenance dose on day 29	1 starter kit	0
		<input type="checkbox"/> HS Maintenance: Inject 40mg subcutaneously every week	28 Day Supply	
Ilumya®	<input type="checkbox"/> 100mg Prefilled Syringe	<input type="checkbox"/> Induction: Inject 100mg under the skin at week 0 and 4, then every 12 weeks thereafter <input type="checkbox"/> Maintenance: Inject 100mg under the skin every 12 weeks	28 Day Supply	0
			84 Day Supply	
Otezla®	<input type="checkbox"/> 28 Day Starter Pack	<input type="checkbox"/> Induction: Take as follows: Day 1 - 10mg in AM, Day 2 - 10mg in AM/10mg in PM, Day 3 - 10mg in AM/20mg in PM, Day 4 - 20mg in AM/20mg in PM, Day 5 - 20mg in AM/30mg in PM, Day 6 and after 30mg twice daily	28 Day Supply	0
Otezla®	<input type="checkbox"/> 30mg tablets	<input type="checkbox"/> Maintenance: Take 30mg by mouth twice a day. <input type="checkbox"/> Bridge: Take 30mg by mouth twice a day, dispensed by OSP.	30 Day Supply	
			14 Day Supply	12
Siliq®	<input type="checkbox"/> 210mg Prefilled Syringe	<input type="checkbox"/> Induction: Inject 210mg under the skin at week 0, and 1 <input type="checkbox"/> Maintenance: Inject 210mg under the sk-in every 2 weeks starting at day 15	14 Day Supply	0
			28 Day Supply	
Stelara®	<input type="checkbox"/> 45mg Prefilled syringe <input type="checkbox"/> 90mg Prefilled syringe	<input type="checkbox"/> < 100kg Body Weight: Inject 45mg subcutaneously on Day 1, again after 4 weeks, then every 12 weeks after. <input type="checkbox"/> >100kg Body Weight: Inject 90mg subcutaneously on Day 1, again after 4 weeks, then every 12 weeks after.	28 Day Supply	
			84 Day Supply	
Taltz®	<input type="checkbox"/> 80mg Prefilled syringe <input type="checkbox"/> 80mg Pen	<input type="checkbox"/> Starting Dose: Inject under the skin two 80 mg injections on Day 1. <input type="checkbox"/> Starting Dose w/ Induction: Inject under the skin two 80 mg injections on Day 1, then begin first induction dose 2 weeks later. <input type="checkbox"/> Induction Dose: Inject under the skin one 80 mg injection every 2 weeks (weeks 4-10) <input type="checkbox"/> Final Induction Dose: Inject under the skin one 80 mg injection (week 12). <input type="checkbox"/> Maintenance Dose: Inject under the skin one 80 mg injection every 4 weeks.	2	0
			3	0
			2	1
			1	0
			1	
Tremfya®	<input type="checkbox"/> 100mg Prefilled Syringe	<input type="checkbox"/> Induction: Inject 100mg under the skin at week 0, then begin maintenance at week 4. <input type="checkbox"/> Maintenance: Inject 100mg under the skin every 8 weeks.	28 Day Supply	0
			56 Day Supply	

Deliver to: Patient's Home
 Physician's Office
 1st dose to MD's Office, remaining refills to patient's home

Training: Patient has received injection training
 Physician's office to provide injection training
 Pharmacy to coordinate injection training

Prescriber's Signature (signature required. NO STAMPS) _____ Date _____

By signing this form and utilizing our services, you are authorizing Benevere and it's employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.